Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

Pfizer (PFE) stock in focus as Sally Susman, the company's Chief Corporate Affairs Officer, plans to depart after 18 years.

One of the best known communications executives in corporate America, Susman worked at Pfizer for nearly two decades after ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.

In the latest close session, Pfizer (PFE) was up +1.51% at $25.62. The stock's performance was ahead of the S&P 500's daily loss of 0.07%. Elsewhere, the Dow saw a downswing of 0.37%, while the ...

The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified ...

Changing market conditions and consumer tastes and preferences have weighed on these businesses. Investors can learn a lot ...

Trump administration policy tug-of-war between big medical groups that want COVID vaccines back on CDC schedule for healthy ...